METHOD FOR ASSESSING THE RISK OF PROGRESSION OF LIVER FIBROSIS IN VIRAL HEPATITIS Russian patent published in 2022 - IPC A61B8/13 A61B8/08 

FIELD: medicine.

SUBSTANCE: invention relates to medicine, namely to radiation diagnostics, and can be used to assess the risk of progression of liver fibrosis in viral hepatitis. To do this, liver elastography is performed to detect fibrosis. Then, a mode of marking proton spins with a magnetic field in arterial blood water molecules (ASL perfusion) is performed with magnetic resonance imaging to obtain maps of volumetric blood flow in the abdominal aorta (ABF) in ml/100 g/min and volumetric blood flow in the hepatic artery (HBF) in ml/100 g/min. After that, the fibrosis progression coefficient ΔP=P_ABF/P_HBF is calculated, where P_ABF is the coefficient of volumetric blood flow in the abdominal aorta, P_HBF is the coefficient of volumetric blood flow in the hepatic artery. If ΔP≥1.5, there is no risk of fibrosis progression. If ΔP<1.5, there is a risk of fibrosis progression. If there is no risk of fibrosis progression, control is carried out after 3 months, if there is a risk of fibrosis progression, after 1 month.

EFFECT: method provides the most accurate non-invasive assessment of the risk of liver fibrosis progression in viral hepatitis by determining the fibrosis progression coefficient, which provides timely implementation and correction of therapeutic and diagnostic measures.

1 cl, 5 ex